198 related articles for article (PubMed ID: 36306018)
1. Cardiotoxicity linked to anticancer agents and cardioprotective strategy.
Khairnar SI; Kulkarni YA; Singh K
Arch Pharm Res; 2022 Oct; 45(10):704-730. PubMed ID: 36306018
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
3. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection.
Madonna R; Cadeddu C; Deidda M; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Spallarossa P; Tocchetti CG; Zito C; Mercuro G
Heart Fail Rev; 2015 Sep; 20(5):621-31. PubMed ID: 26168714
[TBL] [Abstract][Full Text] [Related]
4. Natural Bioactive as a Potential Therapeutic Approach for the Management of Cyclophosphamide-induced Cardiotoxicity.
Iqubal A; Wasim M; Ashraf M; Najmi AK; Syed MA; Ali J; Haque SE
Curr Top Med Chem; 2021; 21(29):2647-2670. PubMed ID: 34392821
[TBL] [Abstract][Full Text] [Related]
5. Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity: SGLT-2 inhibitors and chemotherapy-induced cardiotoxicity.
Vafa RG; Sabahizadeh A; Mofarrah R
Curr Probl Cardiol; 2024 Mar; 49(3):102350. PubMed ID: 38128634
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.
Varghese SS; Eekhoudt CR; Jassal DS
Mol Cell Biochem; 2021 Aug; 476(8):3099-3109. PubMed ID: 33835331
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity.
Liu H; Wang H; Xiang D; Guo W
Mini Rev Med Chem; 2017; 17(1):44-50. PubMed ID: 27337969
[TBL] [Abstract][Full Text] [Related]
8. Strategies to increase cardioprotection through cardioprotective chemokines in chemotherapy-induced cardiotoxicity.
Haybar H; Shahrabi S; Deris Zayeri Z; Pezeshki S
Int J Cardiol; 2018 Oct; 269():276-282. PubMed ID: 30054148
[TBL] [Abstract][Full Text] [Related]
9. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.
Caspani F; Tralongo AC; Campiotti L; Asteggiano R; Guasti L; Squizzato A
Intern Emerg Med; 2021 Mar; 16(2):477-486. PubMed ID: 33011930
[TBL] [Abstract][Full Text] [Related]
10. Routine Prophylactic Cardioprotective Therapy Should Not Be Given to All Recipients of Potentially Cardiotoxic Cancer Chemotherapy.
Davis MK; Virani SA
Can J Cardiol; 2016 Jul; 32(7):926-30. PubMed ID: 27245087
[TBL] [Abstract][Full Text] [Related]
11. The Role of Flavonoids as a Cardioprotective Strategy against Doxorubicin-Induced Cardiotoxicity: A Review.
Syahputra RA; Harahap U; Dalimunthe A; Nasution MP; Satria D
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209107
[TBL] [Abstract][Full Text] [Related]
12. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game.
Dos Santos Arruda F; Tomé FD; Miguel MP; de Menezes LB; Nagib PRA; Campos EC; Soave DF; Celes MRN
Curr Pharm Des; 2019; 25(2):109-118. PubMed ID: 30864503
[TBL] [Abstract][Full Text] [Related]
14. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs.
Al-Hussaniy HA; Alburghaif AH; Alkhafaje Z; Al-Zobaidy MAJ; Alkuraishy HM; Mostafa-Hedeab G; Azam F; Al-Samydai AM; Al-Tameemi ZS; Naji MA
J Med Life; 2023 Apr; 16(4):491-500. PubMed ID: 37305823
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
17. Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.
Serini S; Ottes Vasconcelos R; Nascimento Gomes R; Calviello G
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231904
[TBL] [Abstract][Full Text] [Related]
18. Routine Prophylactic Cardioprotective Therapy Should Be Given to All Recipients at Risk of Cardiotoxicity From Cancer Chemotherapy.
Abdel-Qadir H; Nolan MT; Thavendiranathan P
Can J Cardiol; 2016 Jul; 32(7):921-5. PubMed ID: 27343746
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity.
Cadeddu Dessalvi C; Deidda M; Noto A; Madeddu C; Cugusi L; Santoro C; López-Fernández T; Galderisi M; Mercuro G
Antioxid Redox Signal; 2021 Mar; 34(7):572-588. PubMed ID: 32151144
[No Abstract] [Full Text] [Related]
20. Cardiovascular disease in adult survivors of childhood cancer.
Lipshultz SE; Franco VI; Miller TL; Colan SD; Sallan SE
Annu Rev Med; 2015; 66():161-76. PubMed ID: 25587648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
